Japan approves NovoCure (NASDAQ: NVCR) Optune Lua with PD-1/PD-L1 drugs

Rhea-AI Filing Summary

NovoCure Limited filed a current report to highlight a regulatory milestone in Japan. On September 15, 2025, Japan’s Ministry of Health, Labour and Welfare approved NovoCure’s Optune Lua® device for use together with PD-1/PD-L1 inhibitor drugs to treat adult patients with unresectable advanced or recurrent non-small cell lung cancer whose disease has progressed after platinum-based chemotherapy. This expands Optune Lua’s approved treatment setting in Japan for a difficult-to-treat lung cancer population. The company released the news in a press release that is furnished as an exhibit to the report.

Positive

• Japanese MHLW approval for Optune Lua in combination with PD-1/PD-L1 inhibitors for unresectable advanced/recurrent NSCLC post–platinum chemotherapy expands its treated patient population in a major market.

Negative

• None.

Insights

Biopharma regulatory and markets analyst

Japanese approval broadens Optune Lua’s use in advanced lung cancer.

The key development is Japan’s Ministry of Health, Labour and Welfare approval of Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer after progression on platinum-based chemotherapy. This effectively connects NovoCure’s Tumor Treating Fields therapy with widely used immuno-oncology drugs in a defined Japanese lung cancer setting.

The combined-use indication is important because PD-1/PD-L1 inhibitors are now standard components of NSCLC care, and the approval explicitly permits their concurrent use with Optune Lua in Japan. While the excerpt does not quantify market size or financial impact, expanding the approved label in a major healthcare market generally increases the potential patient pool and supports broader clinical adoption where reimbursed.

Investors may focus on how this new indication is implemented in practice in Japan, including physician uptake, integration into treatment pathways for patients who have progressed on platinum-based chemotherapy, and any future disclosures on utilization or revenue contribution tied to Optune Lua in this NSCLC setting.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001645113false00016451132024-08-262025-10-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

September 15, 2025

Date of Report (date of earliest event reported)

NovoCure Limited

(Exact name of registrant as specified in its charter)

Jersey			001-37565						98-1057807
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street			St. Helier			Jersey			JE2 4UF
(Address of Principal Executive Offices)									(Zip Code)

+44 (0) 15 3475 6700

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Ordinary Shares, no par value			NVCR			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

o

Item 7.01     Regulation FD Disclosure.

On September 15, 2025, the Company issued a press release announcing that that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.

The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d)    Exhibits

Exhibit No.			Description
99.1			Press Release of NovoCure Limited, dated September 15, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited

(Registrant)

Date: September 15, 2025

By: /s/ Christoph Brackmann

Name: Christoph Brackmann

Title: Chief Financial Officer

FAQ

What did NovoCure (NVCR) announce in this 8-K filing?

NovoCure reported that on September 15, 2025, Japan’s Ministry of Health, Labour and Welfare approved its Optune Lua® therapy for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer who have progressed on or after platinum-based chemotherapy.

Which patient population is covered by the new Optune Lua approval in Japan for NVCR?

The approval applies to adult patients in Japan with unresectable advanced or recurrent non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy, allowing treatment with Optune Lua together with PD-1/PD-L1 inhibitor drugs.

Which regulatory body granted the new Optune Lua approval mentioned by NovoCure (NVCR)?

The approval was granted by Japan’s Ministry of Health, Labour and Welfare (MHLW), the national authority overseeing healthcare approvals in Japan.

Does the 8-K indicate that NovoCure’s press release is part of its filed financial statements?

No. The company states that the information under the Regulation FD disclosure section, including the press release, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings unless specifically referenced.

What exhibit did NovoCure (NVCR) attach related to this Japanese approval?

NovoCure attached Exhibit 99.1, which is the press release dated September 15, 2025 describing Japan’s MHLW approval of Optune Lua, and Exhibit 104 for the cover page interactive data file.

Who signed the NovoCure (NVCR) 8-K related to the Optune Lua approval?

The report was signed on behalf of NovoCure Limited by Christoph Brackmann, the company’s Chief Financial Officer.